[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0948509T3 - 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater - Google Patents

2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater

Info

Publication number
DK0948509T3
DK0948509T3 DK97953888T DK97953888T DK0948509T3 DK 0948509 T3 DK0948509 T3 DK 0948509T3 DK 97953888 T DK97953888 T DK 97953888T DK 97953888 T DK97953888 T DK 97953888T DK 0948509 T3 DK0948509 T3 DK 0948509T3
Authority
DK
Denmark
Prior art keywords
purin
tetrahydrofuran
diol derivatives
diol
derivatives
Prior art date
Application number
DK97953888T
Other languages
English (en)
Inventor
Brian Cox
Heather Hobbs
Thomas Davis Roper Iv
Suzanne Elaine Keeling
David George Allen
Alison Judith Redgrave
Michael David Barker
Joanna Victoria Osi Phar Geden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626845.3A external-priority patent/GB9626845D0/en
Priority claimed from GBGB9626846.1A external-priority patent/GB9626846D0/en
Priority claimed from GBGB9626852.9A external-priority patent/GB9626852D0/en
Priority claimed from GBGB9720536.3A external-priority patent/GB9720536D0/en
Priority claimed from GBGB9722730.0A external-priority patent/GB9722730D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0948509T3 publication Critical patent/DK0948509T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97953888T 1996-12-24 1997-12-22 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater DK0948509T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9626845.3A GB9626845D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626846.1A GB9626846D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626852.9A GB9626852D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9720536.3A GB9720536D0 (en) 1997-09-27 1997-09-27 Chemical compounds
GBGB9722730.0A GB9722730D0 (en) 1997-10-29 1997-10-29 Chemical compounds
PCT/EP1997/007197 WO1998028319A1 (en) 1996-12-24 1997-12-22 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Publications (1)

Publication Number Publication Date
DK0948509T3 true DK0948509T3 (da) 2003-02-24

Family

ID=27517393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97953888T DK0948509T3 (da) 1996-12-24 1997-12-22 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater

Country Status (36)

Country Link
US (2) US6426337B1 (da)
EP (1) EP0948509B1 (da)
JP (1) JP4156035B2 (da)
KR (1) KR20000069682A (da)
CN (1) CN1246124A (da)
AP (1) AP1105A (da)
AR (1) AR011044A1 (da)
AT (1) ATE226212T1 (da)
AU (1) AU733684B2 (da)
BG (1) BG63310B1 (da)
BR (1) BR9714082A (da)
CA (1) CA2275271A1 (da)
CO (1) CO4940488A1 (da)
CZ (1) CZ230999A3 (da)
DE (1) DE69716468T2 (da)
DK (1) DK0948509T3 (da)
EA (1) EA001714B1 (da)
EE (1) EE04019B1 (da)
ES (1) ES2186015T3 (da)
GE (1) GEP20022656B (da)
HU (1) HUP0000673A3 (da)
ID (1) ID22271A (da)
IL (1) IL130547A0 (da)
IS (1) IS5089A (da)
NO (1) NO312840B1 (da)
NZ (1) NZ336332A (da)
OA (1) OA11071A (da)
PE (1) PE27499A1 (da)
PL (1) PL334218A1 (da)
PT (1) PT948509E (da)
SI (1) SI0948509T1 (da)
SK (1) SK86599A3 (da)
TR (1) TR199901905T2 (da)
TW (1) TW528755B (da)
WO (1) WO1998028319A1 (da)
YU (1) YU29099A (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
NZ509030A (en) * 1998-06-23 2003-07-25 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9930082D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
WO2002072067A2 (en) * 2001-03-12 2002-09-19 Glaxo Group Limited Pharmaceutical aerosol formulation
JP2002338593A (ja) * 2001-05-22 2002-11-27 Ajinomoto Co Inc β−D−リボフラノース誘導体又はその光学異性体の製造方法
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
PL1758596T3 (pl) * 2004-05-26 2011-01-31 Inotek Pharmaceuticals Corp Pochodne purynowe jako agoniści receptora adenozynowgo A1, oraz sposoby ich zastosowania
JP5011112B2 (ja) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション プリン誘導体を含有する炎症性疾患の治療用医薬
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2010123931A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
WO2011069918A1 (en) 2009-12-09 2011-06-16 Glaxo Group Limited Novel medical use
PL2523669T3 (pl) 2010-01-11 2017-06-30 Inotek Pharmaceuticals Corporation Połączenie, zestaw i sposób obniżania ciśnienia wewnątrzgałkowego
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INTRAOCULAR PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA) DERIVATIVES OR CPA PRODRUGS
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US9993444B2 (en) 2011-01-10 2018-06-12 Invion, Inc. Use of beta-adrenergic inverse agonists for smoking cessation
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
PL2834241T3 (pl) 2012-03-05 2021-07-12 Gilead Calistoga Llc Formy polimorficzne (s)-2-(1-(9h-puryn-6-yloamino)propylo)-5-fluoro-3-fenylochinazolin-4(3h)-onu
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
AU2013317791B2 (en) * 2012-09-21 2018-05-10 Midwestern University Inhibitors of beta-hydrolase for treatment of cancer
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン, エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
AU2014239222A1 (en) 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation Ophthalmic formulations
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール3−キナーゼ阻害剤のためのプロセス方法
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ, インコーポレイテッド ホスファチジルイノシトール3−キナーゼ阻害剤
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
JP7125144B2 (ja) 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ, インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
JP2022537358A (ja) * 2019-06-20 2022-08-25 キャリセラ バイオサイエンシーズ, インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796700A (en) 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
DE3576344D1 (de) 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
PT86660B (pt) 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
PT95628A (pt) 1989-10-19 1991-09-30 Searle & Co Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP2505085B2 (ja) 1990-09-25 1996-06-05 ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド 抗昇圧および抗虚血特性を有する化合物
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
JPH08506343A (ja) 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
WO1998028319A1 (en) 1998-07-02
NZ336332A (en) 2000-12-22
OA11071A (en) 2002-11-18
HUP0000673A2 (hu) 2001-06-28
CN1246124A (zh) 2000-03-01
US6426337B1 (en) 2002-07-30
YU29099A (sh) 2002-06-19
AP9901572A0 (en) 1999-06-30
TW528755B (en) 2003-04-21
SK86599A3 (en) 2000-05-16
DE69716468T2 (de) 2003-05-28
US6528494B2 (en) 2003-03-04
AR011044A1 (es) 2000-08-02
PE27499A1 (es) 1999-03-30
BR9714082A (pt) 2000-05-09
EP0948509A1 (en) 1999-10-13
ID22271A (id) 1999-09-23
BG103518A (en) 2000-01-31
EP0948509B1 (en) 2002-10-16
NO993114L (no) 1999-08-23
IS5089A (is) 1999-06-22
AU733684B2 (en) 2001-05-24
KR20000069682A (ko) 2000-11-25
JP2001506668A (ja) 2001-05-22
CZ230999A3 (cs) 1999-12-15
PT948509E (pt) 2003-03-31
EE04019B1 (et) 2003-04-15
BG63310B1 (bg) 2001-09-28
ES2186015T3 (es) 2003-05-01
CA2275271A1 (en) 1998-07-02
NO312840B1 (no) 2002-07-08
HUP0000673A3 (en) 2003-01-28
DE69716468D1 (de) 2002-11-21
GEP20022656B (en) 2002-03-25
NO993114D0 (no) 1999-06-23
ATE226212T1 (de) 2002-11-15
EE9900312A (et) 2000-02-15
AU5762298A (en) 1998-07-17
EA199900494A1 (ru) 2000-02-28
IL130547A0 (en) 2000-06-01
PL334218A1 (en) 2000-02-14
US20020086850A1 (en) 2002-07-04
AP1105A (en) 2002-09-04
SI0948509T1 (en) 2003-06-30
TR199901905T2 (xx) 1999-10-21
JP4156035B2 (ja) 2008-09-24
EA001714B1 (ru) 2001-08-27
CO4940488A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
DK0948509T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater
DE69903708D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
IS5779A (is) 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
DK1056759T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater
NO20006521D0 (no) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivater
ZA9711535B (en) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
SI1056759T1 (en) 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
ZA991154B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA99689B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.